← Back to Search

18F fluciclovine for Brain Tumor (PURSUE Trial)

Phase 2
Waitlist Available
Led By Rupesh Kotecha, MD
Research Sponsored by Blue Earth Diagnostics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the time of administration of 18f fluciclovine until 1 day post-18f-fluciclovine administration.
Awards & highlights

PURSUE Trial Summary

This trial is testing a new imaging agent to see if it can help doctors better detect brain metastases (cancer that has spread to the brain from elsewhere in the body).

Eligible Conditions
  • Brain Tumor

PURSUE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of administration of 18f fluciclovine until 1 day post-18f-fluciclovine administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of administration of 18f fluciclovine until 1 day post-18f-fluciclovine administration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
Specificity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
Secondary outcome measures
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases Based on Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake
Specificity of Different Thresholds of Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake.
Treatment-emergent Adverse Events

Side effects data

From 2021 Phase 2 trial • 23 Patients • NCT04410367
4%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
18F-Fluciclovine Injection

PURSUE Trial Design

1Treatment groups
Experimental Treatment
Group I: PatientsExperimental Treatment1 Intervention
Single intravenous administration of 18F fluciclovine for PET Scan
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F fluciclovine
2020
Completed Phase 3
~180

Find a Location

Who is running the clinical trial?

Blue Earth DiagnosticsLead Sponsor
38 Previous Clinical Trials
2,964 Total Patients Enrolled
Precision For MedicineIndustry Sponsor
4 Previous Clinical Trials
454 Total Patients Enrolled
Eugene Teoh, MDStudy DirectorBlue Earth Diagnostics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Neuro-OncologyJournal
Letter Regarding “contribution of PET Imaging to Radiotherapy Planning and Monitoring in Glioma Patients—a Report of the PET/RANO Group
Kotecha, Rupesh, Mariam Aboian, Seyed Ali Nabavizadeh, Ephraim E Parent, Daniel M Trifiletti, and Samuel T Chao. 2021. “Letter Regarding “contribution of PET Imaging to Radiotherapy Planning and Monitoring in Glioma Patients—a Report of the PET/RANO Group”: 18f-fluciclovine and Target Volume Delineation”. Neuro-oncology. Oxford University Press (OUP). doi:10.1093/neuonc/noab097.
clinicaltrials.govStudy
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
2020. "Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04410367.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top